Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.
Tag Archive for: NSCLC
Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III NSCLC trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb.
Bristol Myers Squibb’s $4.8 billion acquisition of Mirati pays off with strong data from the KRYSTAL-12 study of Krazati, showing that the KRAS inhibitor significantly improves progression-free survival.
Novocure said on Wednesday that its device met the main goal of a late-stage trial by slowing the progression of cancer to the brain in patients with a type of lung cancer, sending its shares up about 33% in before-the-bell trading.
The company stated that a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.
Rybrevant has been approved for use with carboplatin and pemetrexed in the first-line treatment of locally advanced or metastatic non-small cell lung cancer with exon 20 insertion mutations in the EGFR gene.
The financing was secured from life sciences investment company Abingworth and will help Gilead run “select clinical studies” of Trodelvy.
When given concurrently with chemoradiotherapy, AstraZeneca’s Imfinzi in a late-stage lung cancer study did not lead to significant improvements in progression-free survival versus chemoradiotherapy alone.
Early stage ALK-positive non-small cell lung cancer patients treated with Roche’s Alecensa saw an “unprecedented” 76% drop in the risk of recurrence or death, the company announced.
The abstracts, made available Tuesday ahead of the European Society for Medical Oncology Congress 2023, show strong efficacy data from some promising non-small cell lung cancer treatments.
